Bevacizumab Should Be Held for Thoracentesis
Bevacizumab must be withheld for at least 28 days prior to any elective surgical procedure, including thoracentesis, and should not be resumed until adequate wound healing is established. 1
Timing for Holding Bevacizumab
The FDA-approved prescribing information for bevacizumab (Avastin) provides explicit guidance on procedural timing:
- Withhold bevacizumab for at least 28 days before any elective surgery or invasive procedure 1
- Do not administer bevacizumab for at least 28 days following major surgery 1
- Resume only after adequate wound healing has occurred 1
Clinical Rationale
Bevacizumab inhibits VEGF-A, which is critical for angiogenesis and wound healing. This mechanism creates significant risk for:
- Wound healing complications - any severity warrants holding the drug until adequate healing occurs 1
- Hemorrhagic complications - bevacizumab increases risk of severe or fatal hemorrhages, including pulmonary hemorrhage (2.3% fatal rate in lung cancer patients) 2
- The safety of resuming bevacizumab after wound healing complications has not been established 1
Specific Considerations for Pleural Procedures
While thoracentesis is less invasive than major surgery, the 28-day holding period applies because:
- Pleural procedures create vascular injury requiring normal healing mechanisms 1
- Bevacizumab-treated patients have documented increased bleeding risk even with minor procedures 2, 3
- The drug's half-life necessitates adequate clearance time before procedures involving tissue disruption 1
Resumption After Thoracentesis
Do not restart bevacizumab until:
- At least 28 days have elapsed since the procedure 1
- Adequate wound healing at the puncture site is confirmed 1
- No ongoing bleeding or wound complications are present 1
Critical Caveat
If necrotizing fasciitis develops as a wound healing complication, permanently discontinue bevacizumab - do not attempt to restart 1. This represents an absolute contraindication to further therapy.